Australia's most trusted
source of pharma news
Monday, 01 July 2024
Posted 18 December 2023 AM
A move by Woolies-backed telehealth company Eucalyptus raises questions for both Novo Nordisk and patients, as it seems to skirt the edge of the TGA act.
Eucalyptus, also backed by Blackbird VC, announced that its two brands Juniper and Pilot would begin selling semaglutide products produced by compounding pharmacies rather than by Novo Nordisk, according to a report in the Australian Financial Review newspaper.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.